NCT05702879View on ClinicalTrials.gov

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Ulcerative Colitis
Interventions
DRUG

Ozanimod

Start of standard therapy

DRUG

TNF Inhibitor

Start of standard therapy

DRUG

Steroids

Start of standard therapy

DRUG

Vedolizumab

Start of standard therapy

DRUG

Ustekinumab

Start of standard therapy

Trial Locations (1)

3013

RECRUITING

University Hospital Bern Inselspital, Bern

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success | Biotech Hunter | Biotech Hunter